Pulmonx to Present at the Canaccord Genuity 42nd Annual Growth Conference

Rhea-AI Summary

Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Canaccord Genuity 42nd Annual Growth Conference in Boston on August 10, 2022, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be accessible on the company's Investors page. Pulmonx is known for its Zephyr® Endobronchial Valve, which has treated over 25,000 patients worldwide, and received FDA premarket approval as a breakthrough device.

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Canaccord Genuity 42nd Annual Growth Conference in Boston. Management is scheduled to present on Wednesday, August 10, 2022, at 1:00 PM PT / 4:00 PM ET.

A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for severe lung disease. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA premarket approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, with over 100,000 valves used to treat more than 25,000 patients. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.

Pulmonx®, Chartis®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005979/en/

Brian Johnston

Gilmartin Group

investors@pulmonx.com

Source: Pulmonx Corporation

FAQ

When is Pulmonx's presentation at the Canaccord Genuity 42nd Annual Growth Conference?

Pulmonx's presentation is scheduled for August 10, 2022, at 1:00 PM PT / 4:00 PM ET.

Where can I watch the live webcast of Pulmonx's presentation?

The live and archived webcast will be available on the 'Investors' section of Pulmonx's website.

What products does Pulmonx offer for treating lung disease?

Pulmonx offers the Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, and StratX® Lung Analysis Platform.

What is the significance of the Zephyr Valve for Pulmonx?

The Zephyr Valve has received FDA premarket approval and is recognized as a breakthrough device, having treated more than 25,000 patients.

How many countries is the Zephyr Valve available in?

The Zephyr Valve is commercially available in over 25 countries.